Delivery Order SPE2DB20D1100-SPE2DB25FE5N0
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,559.88 to AmerisourceBergen Drug Corp for Pioglitazone-Metformin 15-850 mg tablets (60-count supply). This firm fixed-price, competitively awarded contract was executed on July 29, 2025, with an ultimate completion date of July 30, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, and represents a standard transaction within the company's extensive federal medical...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $8,707.88, is for the delivery of Pioglitazone-Metformin 15-500 60S, a pharmaceutical product. The contract is a firm fixed-price delivery order, with an ultimate completion date of April 15, 2025. This award is associated with a larger Indefinite Delivery Contract (IDC) that...
- This is a $5,299.96 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Pioglitazone-Metformin 15-850 60S, a medication used to manage diabetes. The contract has an ultimate completion date of December 26, 2023. AmerisourceBergen Drug Corp holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The order, valued at $5,031.24, is for the supply of Pioglitazone-Metformin 15-500 60s, a medication used to treat type 2 diabetes. The delivery order is placed under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle...
- The Defense Logistics Agency (DLA) awarded a $1,102.08 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Metformin HCL 500 mg tablets (1000-count units). This non-set-aside contract was awarded on August 22, 2025, with an ultimate completion date of August 25, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $1,250.16 delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Metformin HCL ER 500 mg tablets (180-count units). This competitively awarded, firm fixed-price contract is classified as a child award under a larger indefinite delivery contract vehicle and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania, with a completion deadline of September 3, 2025. The contract represents a routine...
- The Defense Logistics Agency awarded a delivery order valued at $1,102.08 to AmerisourceBergen Drug Corp for the supply of Metformin HCL 500 mg tablets in quantities of 1,000 units. The contract employs firm fixed-price pricing with no set-aside designation, indicating competitive award through open procurement. Performance is scheduled for completion by August 21, 2025, with the product to be delivered to the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Metformin HCL ER 500 mg tablets (1,000 count) with a ceiling value of $2,523.13. The award, made on September 9, 2025, represents a firm fixed-price delivery order with an ultimate completion date of September 10, 2025. This order was competitively awarded with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for pharmaceutical supplies on July 29, 2025, with an ultimate completion date of July 30, 2025. The contract, valued at $1,913.15 under firm fixed pricing, covers the delivery of Dapagliflozin 10 mg tablets (30-count packaging), a diabetes medication. This is a non-set-aside, competitively awarded delivery order issued against AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $21,804.19 to AmerisourceBergen Drug Corp for the supply of Pioglitazone HCL 45 mg tablets (30-count units). This competitively awarded, firm fixed-price delivery order was executed on August 21, 2025, with an ultimate completion date of August 22, 2025, and represents a non-set-aside procurement. The contract will be performed at AmerisourceBergen Drug Corp's corporate office location in Conshohocken, Pennsylvania, where...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE5N0Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Pioglitazone-Metformin 15-850mg in 60-count quantities, with a contract ceiling value of $2,068.17. This competitive, non-set-aside delivery order utilizes firm fixed pricing and is scheduled for completion by September 10, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement serving military and veteran healthcare systems. The order represents a child delivery order under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which provides comprehensive pharmaceutical and medical supply support globally. This delivery order exemplifies routine pharmaceutical procurement through AmerisourceBergen's established federal contract vehicle, supplying diabetes medication to support Department of Defense healthcare operations. The company maintains a substantial portfolio of federal contracts with DLA covering diverse therapeutic categories including specialty medications, generics, vaccines, and medical devices, positioning it as a key logistics provider for military medicine. The modest contract value and expedited completion timeline indicate this is a routine replenishment order fulfilling immediate medical supply requirements within the broader pharmaceutical prime vendor framework supporting Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 9/9/25 |